167 related articles for article (PubMed ID: 18324929)
21. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
Wallace TM; Levy JC; Matthews DR
Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
[TBL] [Abstract][Full Text] [Related]
22. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
23. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
24. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
Fukui Y; Masui S; Osada S; Umesono K; Motojima K
Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
[TBL] [Abstract][Full Text] [Related]
25. Induction of uncoupling protein in brown adipose tissue. Synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent.
Foellmi-Adams LA; Wyse BM; Herron D; Nedergaard J; Kletzien RF
Biochem Pharmacol; 1996 Sep; 52(5):693-701. PubMed ID: 8765467
[TBL] [Abstract][Full Text] [Related]
26. In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice.
Shimokawa T; Kato M; Watanabe Y; Hirayama R; Kurosaki E; Shikama H; Hashimoto S
Biochem Biophys Res Commun; 1998 Oct; 251(1):374-8. PubMed ID: 9790963
[TBL] [Abstract][Full Text] [Related]
27. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
28. Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.
Pfützner A; Schöndorf T; Hanefeld M; Lübben G; Kann PH; Karagiannis E; Wilhelm B; Forst T
Horm Metab Res; 2009 Mar; 41(3):202-6. PubMed ID: 19224430
[TBL] [Abstract][Full Text] [Related]
29. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
30. Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients.
Esterson YB; Zhang K; Koppaka S; Kehlenbrink S; Kishore P; Raghavan P; Maginley SR; Carey M; Hawkins M
J Investig Med; 2013 Dec; 61(8):1152-60. PubMed ID: 24141239
[TBL] [Abstract][Full Text] [Related]
31. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.
Tripathy D; Cobb JE; Gall W; Adam KP; George T; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Reaven PD; Musi N; Ferrannini E; DeFronzo RA
J Clin Endocrinol Metab; 2015 May; 100(5):1855-62. PubMed ID: 25603459
[TBL] [Abstract][Full Text] [Related]
32. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans.
Stefan N; Hennige AM; Staiger H; Machann J; Schick F; Schleicher E; Fritsche A; Häring HU
Diabetes Care; 2007 May; 30(5):1173-8. PubMed ID: 17259477
[TBL] [Abstract][Full Text] [Related]
33. Visfatin is an adipokine, but it is not regulated by thiazolidinediones.
Hammarstedt A; Pihlajamäki J; Rotter Sopasakis V; Gogg S; Jansson PA; Laakso M; Smith U
J Clin Endocrinol Metab; 2006 Mar; 91(3):1181-4. PubMed ID: 16394088
[TBL] [Abstract][Full Text] [Related]
34. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
[TBL] [Abstract][Full Text] [Related]
35. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.
Serlie MJ; Allick G; Groener JE; Ackermans MT; Heijligenberg R; Voermans BC; Aerts JM; Meijer AJ; Sauerwein HP
J Clin Endocrinol Metab; 2007 Jan; 92(1):166-71. PubMed ID: 17062758
[TBL] [Abstract][Full Text] [Related]
36. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients.
Takebayashi K; Suetsugu M; Wakabayashi S; Aso Y; Inukai T
J Clin Endocrinol Metab; 2007 Jul; 92(7):2712-9. PubMed ID: 17440021
[TBL] [Abstract][Full Text] [Related]
37. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes.
Moody AJ; Molina-Wilkins M; Clarke GD; Merovci A; Solis-Herrera C; Cersosimo E; Chilton RJ; Iozzo P; Gastaldelli A; Abdul-Ghani M; DeFronzo RA
Diabetes Obes Metab; 2023 Feb; 25(2):426-434. PubMed ID: 36204991
[TBL] [Abstract][Full Text] [Related]
38. The adipose tissue endocrine mechanism of the prophylactic protective effect of pioglitazone in high-fat diet-induced insulin resistance.
Gong Y; Li J; Li C; Mu Y; Xiao Y; Tian H; Pan C; Liu Y
J Int Med Res; 2012; 40(4):1304-16. PubMed ID: 22971482
[TBL] [Abstract][Full Text] [Related]
39. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
Bajaj M; Suraamornkul S; Hardies LJ; Pratipanawatr T; DeFronzo RA
Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
[TBL] [Abstract][Full Text] [Related]
40. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
